Roland Magnusson
Chinese regulators have accepted HUTCHMED’s (NASDAQ:HCM) application for priority review for the drug combination Orpathys and Tagrisso in the treatment of certain patients with EGFR-positive non-small cell lung cancer, or NSCLC.
The Chinese drugmaker is seeking to have the combination